Some of drug-resistant mutants of HIV-1 protease (PR), such as a clinically-relevant drugresistant PR mutant (Flap+ (I54V) ) containing L10I, G48V, I54V and V82A mutations, produce significant changes in the balance between entropy and enthalpy of the drug-PR interactions, compared to the wild-type (WT) PR. Here, to gain a comprehensive understanding of the entropy-enthalpy compensation effects, we compared nuclear magnetic resonance (NMR), fluorescence spectroscopy and isothermal titration calorimetry (ITC) data of a WT PR with Flap+ (I54V) and related mutants: (1) Flap+ (I54V) ; (2) Flap+ (I54A) which evolves from Flap+ (I54V) in the continued presence of inhibitor yet does not exhibit entropy-enthalpy compensation; and (3) Flap+ (I54) , a control mutant that contains only L10I, G48V and V82A mutations. Our data indicate that WT and Flap+ (I54A) show enthalpy-driven inhibitor-interaction, while Flap+ (I54) and Flap+ (I54V) exhibit entropy-driven inhibitor interaction. Interestingly, Flap+ (I54A) exhibited significantly slower heat flow in the competitive ITC experiment with a strong binder, darunavir, and a weak binder, acetyl-pepstatin, but did not exhibit such slow heat flow in the direct inhibitor-titration experiments. NMR confirmed replacement of the weak binder by the strong binder in a competitive manner. This difference in the heat flow of the competitive binding experiment compared to the direct experiment can only be explained by assuming an inhibitor-bound intermediate pathway. A similar, but attenuated, tendency for slow heat flow was also detected in the competitive experiment with WT. Overall, our data suggests that an inhibitor-bound intermediate affects the entropy-enthalpy compensation of inhibitor-PR interaction.
Introduction
Human immunodeficiency virus-1 (HIV-1) protease (PR) is an enzyme essential for HIV-1 replication [1] [2] [3] [4] [5] . Although structure-based drug design has resulted in the development of various PR inhibitors, the long-term effectiveness of the inhibitors is hampered by generation of drug-resistance mutations [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . To understand the mechanism of the drug-resistance, thermodynamics studies of inhibitor interactions with PR and various drug-resistant mutants have been conducted for the past two decades [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . However, since the PR concentration range typically used in structure studies is much higher than that required for thermodynamics studies, direct comparison of the findings from these two approaches has been hampered. This gap has hindered identification of the protein states responsible for observations made in thermodynamics studies of inhibitor interactions. As a result, modeling of the mechanism of inhibition has been limited.
Our particular interest is Flap+ (I54V) , which contains a set of clinically-relevant drugresistant PR mutations, L10I, G48V, I54V and V82A ( Fig. 1) . Thermodynamically, inhibitor interactions, such as saquinavir, amprenavir and darunavir (DRV), with Flap+ (I54V) are known to exhibit entropy-enthalpy compensation compared to WT PR: previous isothermal titration calorimetry (ITC) experiments demonstrated that inhibitor-WT interaction was enthalpy driven while inhibitor-Flap+ (I54V) was entropy driven [31] . Thus, Flap+ (I54V) mutations can silently affect the thermodynamics of drug-PR interactions by changing the entropy and enthalpy balance while not significantly changing the total free energy itself. Interestingly, under drug pressures, Flap+ (I54V) evolves to Flap + (I54A) (L10I, G48V, I54A and V82A), but DRV interaction with Flap+ (I54A) does not exhibit the entropy-enthalpy compensation observed for Flap+ (I54V) [32] . Furthermore, the individual mutations, I54V, I54A or G48V, do not show entropy-enthalpy compensation [32] .
These observations have indicated that simple addition of each individual mutation effect cannot explain the thermodynamic changes observed for Flap+ mutants [32] . Such cooperativity of the mutations on the inhibitor-binding thermodynamics was also reported for other, similar PR drugresistance mutants [34] .
The structure of HIV-1 PR has been well characterized ( Fig. 1) : it is a dimer, with the two subunits interfacing via residues in the flaps (residue 45 -55) , the active-site fireman's grip (residues 25 to 27) and the N-and C-terminal β-sheet [35] [36] [37] . They also indirectly interact with each other through inhibitors at the P1 loop, that include one of the Flap mutation sites, residue 82 ( Fig. 1) . The flaps of HIV-1 PR are known to undergo multiple conformations [38] [39] [40] [41] [42] [43] [44] [45] . [49] , and dimer dissociation as a mechanism of inhibition by DRV [50; 51] , which may involve changes of other dimer interface structures. Despite the evidence for multiple conformational states being involved in PR-inhibitor interaction, the thermodynamics of inhibitor-PR interactions have been analyzed assuming only free and bound states.
Recent development in NMR sensitivity have permitted NMR spectra to be recorded for protein samples at low protein concentrations [52] , similar to those used for ITC and fluorescence experiments. Taking advantage of this development, we report our ITC, NMR and fluorescence spectroscopy data of PRs, which were recorded at similar conditions, to understand the molecular mechanism underlying PR-inhibitor interaction. We also introduce an artificial mutant, Flap+ (I54) , which contains mutations L10I, G48V and V82A, and revisit the thermodynamics of inhibitor interaction with Flap+ (I54) , Flap+ (I54V) and Flap+ (I54A) , as well as that with a pseudo WT (pWT) 1 protein that is a backbone of the Flap+ mutants (see details in the Materials and Methods), to identify the underlying mechanism of the entropy-enthalpy compensation. We present (i) the thermodynamics parameters for a weak substrate-analogue inhibitor, acetyl-pepstatin (pepstatin), (ii) the apparent thermodynamics parameters of a strong 
Results

Pepstatin interaction with PRs monitored by ITC
Pepstatin is an aspartic protease inhibitor and has been used to characterize inhibitor-PR interactions [22; 26; 27; 31; 32; 53-55] . We first characterized the thermodynamics parameters of PR interactions with a weak binder, pepstatin, to utilize the parameters for competitive ITC experiments below and to elucidate inhibitor-interaction characteristics of Flap+ mutants against WT. ITC data of pepstatin with pWT and Flap+ mutants were recorded using similar protein concentrations, 20 -30 µM. Isotherms of pWT and Flap+ (I54A) were similar to each other while 1 Abbreviations: pWT, a pseudo wild-type PR containing Q7K, L33I, L63P, C67A, C95A mutations: Flap + (I54V) , a PR containing L10I, G48V, I54V and V82A mutations on the pWT PR backbone; Flap + (I54A) , a PR containing L10I, G48V, I54A and V82A mutations on the pWT PR backbone; Flap + (I54) , a PR containing L10I, G48V and V82A mutations on the pWT PR backbone; pepstatin, acetyl-pepstatin; DRV, darunavir. isotherms of Flap+ (I54) and Flap+ (I54V) were similar to each other ( Fig. 2a-h 
DRV interaction with PRs monitored by ITC
Titration of PRs with a strong binder, DRV, was done in the presence of a weak binder, pepstatin ( Fig. 2i-2p and Table 1 .2). Ideally, the optimal weak binder for competitive ITC experiments would be chosen from a panel of weak binders based on the K D of the strong binder under study [56] . We used a single weak binder, pepstatin, for all PR-DRV interaction studies, to avoid any biases caused by differences in the solubility of weak inhibitors in aqueous solution or differences in the mechanisms of PR interactions of the weak inhibitors. As a result, throughout all DRV-PR interactions, the accuracy of the determined ∆ G and -T∆S may be less for DRV that shows a steep apparent titration profile. However, ∆ H is still accurately determined based on the theoretical equation [56] . In the competitive experiments, all the DRV titrations in the presence of pepstatin showed apparent favorable ∆ H changes, which is in contrast to the pepstatin titration ( Fig. 2i-2p and Table 1 .2) but consistent with previous results [32] . As expected, the molar heat changes were steep in the DRV titration for pWT ( Fig. 2m) , indicative that practical ∆ G accuracy is lower for these proteins. ∆ H values were obtained for Flap+ (I54) and Flap+ (I54V) , respectively ( Table 1. 
3).
As a result, DRV binding of pWT and Flap+ (I54A) was enthalpy-driven while that of Flap+ (I54) and Flap+ (I54V) was entropy-driven ( Fig. 3d-3f) . The observed ∆ G, -14.1 ± 0.22 (kcal/mol), of pWT at pH 5.8, which is a condition that slows down autoproteolysis and suitable for a long-term experiments, is slightly higher than that published previously, -15.0 ± 0.3 (kcal/mol), at pH 5.0 [32] . This may be primarily due to inaccuracy of our experimental condition to detect such low ∆ G binding or secondary because of higher pH in which Asp hydroxyl protonation at the active site may affect to the DRV interaction. Otherwise, thermodynamics parameters of Flap+ (I54A) and Flap+ (I54V) were similar to those published previously [32] .
To reveal the mechanism underlying DRV-pepstatin competition in our experiments, the heat flow of each injection was compared. Since the relative bound fractions at each time point differs among the proteins, both the 3 rd and 5 th injections were assessed (which corresponds to the ~7 min and ~12 min points in Fig. 4a and 4b, respectively). Interestingly, Flap+ (I54A) heat flow was quite different from the others. pWT also shows a slightly slower heat flow compared to Flap+ (I54) and Flap+ (I54V) . Importantly, such slow heat flow was not observed ( Fig. 4a and 4b , green dashed line) in the direct DRV ( Fig. 4c) or pepstatin ( Fig. 2b ) titration of Flap+ (I54A) . Taken together, the thermodynamics changes of inhibitor binding to Flap+ (I54A) and pWT are similar to each other, while those of Flap+ (I54) and Flap+ (I54V) are similar to each other. In Flap+ (I54A) and pWT, the competitive experiments are not simply explained by an on and off model of strong and weak binders to PR.
PR dimer dissociation and folding stability
To understand what states are involved in these PR interactions in solution, we next characterized folding and dimerization of the proteins using intrinsic Trp fluorescence spectroscopy at different protein concentrations and denaturant. Since one of the two Trp residues in PR, residue 6, is located at the dimer interface and exposed to solution upon dimer dissociation [57; 58] , the fluorescence emission of this residue is known to be reduced by dimer dissociation [48] . In pWT and Flap+ mutants, intrinsic Trp fluorescence spectroscopy exhibited linear protein concentration dependence above 0.25 µM ( Fig. 5a ). Through this analysis, dimer dissociation constants of both pWT and Flap+ mutants were determined to be < 0.25 µM, which is consistent with previous results obtained for PR and other mutants [59] and confirms that the PRs used in our ITC experiments were dimers. Since the reduction of fluorescence emission is lower in Flap+ (I54A) compared to pWT, Flap+ (I54) and Flap+ (I54V) , the N-terminal region of Flap+ (I54A) , where Trp 6 is located, may be more mobile or experience greater monomer unfolding compared to the other proteins.
Consistent with this notion, urea denaturation produced overall similar profiles among pWT and Flap mutants ( Fig. 5b) . A slightly lower chemical stability was observed only for Flap+ (I54A) , with a half urea denaturation concentration at 1.8 ± 0.1 M, compared to the others (2.3 -2.5 M, respectively) ( Fig. 5b) . In addition, the fluorescence intensity of Flap+ (I54A) in the absence of urea was 10 -20% lower than that of the others, suggesting the presence of an unfolded component or a slightly different conformation of Flap+ (I54A) compared to the other PR proteins.
NMR probed PR conformation.
PR structural changes that are involved in the inhibitor-PR interaction observed by ITC were also characterized by recording NMR spectra at different protein concentrations and in the presence and absence of inhibitors. We firstly recorded NMR spectra at a protein concentration lower than those used for ITC, 3 µM, to establish proper folding of the PRs. NMR spectral patterns of pWT and Flap+ (I54V) were essentially similar to those published previously, both in apo ( Fig. 5c ) and DRV-bound forms (Fig. 5d ) [60] . Flap+ (I54) spectra also exhibited very similar resonance patterns to those of Flap+ (I54V) in both forms ( Fig. 5c and 5d) . Only the NMR spectrum of Flap+ (I54A) showed a significant unfolded fraction, 29% and 17% in the apo and DRV-bound forms, respectively, estimated from the signal intensity of indole NH resonances ( Fig. 5c and 5d) . These observations of the apo-dimer forms of pWT and Flap+ mutants are consistent with the protein concentration dependence of Trp fluorescence (Fig. 5a) . Similarly, observation of the unfolded component of Flap+ (I54A) is consistent with the lower intensity of Trp fluorescence in this mutant compared to the other mutants ( Fig. 5b) .
Since Flap+ (I54A) exhibited NMR spectral feature that contains unfolded fraction, we further characterized how the unfolded fraction changes at 40 µM protein concentration, which is similar to that used for the ITC experiments. The apo form of Flap+ (I54A) exhibited a similar spectral feature to that at 3 µM ( Fig. 5e, black) . Addition of pepstatin to the -Flap+ (I54A) , after recording the apo spectrum, changed the spectral pattern, presumably from that of the apodimer form to that of the pepstatin-bound form (Fig. 5e, red) . Upon further addition of DRV to the Flap+ (I54A) solution containing pepstatin, the spectral pattern indicated changes from the pepstatin-bound form to the DRV-bound form (Fig. 5f, green) . Importantly, the unfolded fraction in the Flap+ (I54A) , approximately 20%, was not changed upon addition of pepstatin, or further addition of DRV, that mimicked the order of inhibitor competition in the ITC experiments ( Table   2 ). Even when DRV was directly added to the folded apo-Flap+ (I54A), containing 20% unfolded fraction, the unfolded fraction was neither decreased or increased (Table 2 and Fig. S1a) . Only when the protein was folded in the presence of inhibitor did the population of the unfolded fraction became small, 5-8%, indicating that the inhibitors facilitate folding of the protein ( Table   2 and Fig. S1b) . These NMR resonance patterns of Flap+ (I54A) in the presence of DRV are very similar to that of Flap+ (I54) which differs by only one residue from Flap+ (I54A) (Fig. S1c) . These observations suggest that the unfolded fraction in the apo-form of Flap+ (I54A) is a misfolded component or fragments caused by autoproteolysis (Fig. S2) , and does not participate in the inhibitor interaction throughout the experiments ( Table 2 ).
Discussion
In this study, we aimed to understand the molecular mechanism underlying PR-inhibitor interaction, using ITC, NMR and fluorescence spectroscopy. Side-by-side NMR and ITC experiments elucidated the states involved in the thermodynamics changes upon inhibitor-PR interaction. Using this approach, we have made the following overall observations: First, the proteins are folded as a dimer at > µM concentration. Second, ∆ H of inhibitor interaction with pWT and Flap+ (I54A) was more favorable than that of Flap+ (I54) and Flap+ (I54V) , in both DRV and pepstatin interactions. In contrast, -T∆S of Flap+ (I54) and Flap+ (I54V) was more favorable than that of pWT and Flap+ (I54A) . These observations suggest that evolution from I54V to I54A likely makes the inhibitor-binding thermodynamics of the Flap+ mutant more similar to that of pWT.
Differences in the thermodynamics of the inhibitor interactions with the various PR proteins suggest a previously unrecognized inhibitor-bound intermediate. Specifically, a slow heat release was observed in the pepstatin-DRV competitive ITC experiment of Flap+ (I54A) and, less so, of pWT ( Fig. 4a and 4b) . Importantly, such a slow release was not detected in the direct DRV or pepstatin titration experiments ( Fig. 2a, 2b, 4a and 4b) . Since the NMR spectra demonstrated that Flap+ (I54A) binds to pepstatin, which is subsequently replaced by DRV ( Fig.   5e and 5f) , the slow process is not due to differences in inhibitor-on/off rates of the proteins or unfolding of the protein, but is due to an intermediate process. If the intermediate is between the apo and inhibitor-bound states, competitive titration would not show such a difference in heat flow, compared to the direct titration, because DRV binds the apo-form in the equilibrium between the apo and pepstatin-bound forms. Thus, we conclude that the intermediate exists but
is not located on the PR folding pathway (Fig. 6a) and is, instead, located at a step that produces a difference between the direct-titration and competitive titration, i.e, on another inhibitor binding pathway (Fig. 6b) . Thermodynamically, we observed that inhibitor interactions of Flap+ (I54A) and pWT are ∆ H driven while inhibitor interactions of Flap+ (I54) and Flap+ (I54V) are -T∆S driven (Table 1.3) . In the above two-pathway model (Fig. 6b) Structurally, two slightly different dimer forms may exist, as discussed below. Previous studies showed a more open flap conformation in Flap+ (I54V) compared to pWT in the apo form [46; 47] and showed that Flap+ (I54V) exhibits a slightly different conformation, on average less than 1 Å, from the pWT in the DRV bound form [31; 46; 47] (Fig. 1) ; Flap+ (I54A) and pWT showed weaker chemical denaturation compared to Flap+ (I54) and Flap+ (I54V) . The latter model may be valid considering the proposed existence of a PR folding intermediate [48] , intermediate-inhibitor bound forms [49] , and DRV as a dimer dissociation inhibitor [50; 51] . The two subunits of the PR dimer have multiple direct subunit interaction sites, including the flap region, active-site fireman's grip (residues 25 to 27), and the N-and C-terminal β-sheet ( Fig. 1) [ [35] [36] [37] . Indeed, another set of mutations, L10I/ M46I/I54V/V82A/I84V/L90M, that spans both the direct and indirect dimer interfaces, but not a mutant with only the M46I/I54V mutations, also shows the entropy-enthalpy compensation [34] . 
Conclusion
To understand the mechanism of entropy-enthalpy compensation in drug interaction with HIV-1 PR, we performed ITC experiments and NMR for four PRs at protein concentrations similar to each other. Observed differences in the direct and competitive titration heat flow cannot be explained without assuming an inhibitor-bound intermediate in pWT and Flap+ (I54A) . Inhibitor interactions of these proteins involve significant conformational changes. Based on our observations, we propose two inhibitor-binding pathways, one without (entropy favorable) and the other with large conformational changes (enthalpy favorable), which may explain entropyenthalpy compensation detected in the competitive ITC experiments.
Materials and Methods
Protease Expression and Purification
HIV-1 PR with the following amino acid sequence, PQITLWKRPL VTIRIGGQLK EALLDTGADD TVIEEMNLPG KWKPKMIGGI GGFIKVRQYD QIPIEIAGHK AIGTVLVGPT PVNIIGRNLL TQIGATLNF, was used in this study. Note, the construct contains four mutations (Q7K, L33I, C67A, C95A) to reduce autoproteolysis and disulfide-bridge formation [57; 58] and L63P polymorphism [31; 62] . This sequence is called pWT in this study, to distinguish it from WT. Flap+ (I54) contains mutations L10I/G48V/V82A on the pWT construct (DNA2.0, Newark, CA). Flap+ (I54A) and Flap+ (I54V) were yielded by introducing a single amino acid mutation, I54A and I54V, respectively, to Flap+ (I54) . The clones were confirmed by DNA sequencing. We expressed 15 N isotope labeled proteins and purified using the protocols published previously [60] . Proteins were folded with 10 mM acetate at pH 6.0, buffer exchanged to a 20 mM sodium phosphate at pH 5.8, and concentrated approximately to 5 or 50 µM (assuming a dimer). As described below, the protein concentration was re-adjusted in individual experiments. Molecular mass of the proteins used for NMR experiments were checked by Bruker QqTOF mass spectrometer.
Darunavir was obtained from Celia Schiffer's group [62] . All protein concentrations in the manuscript are described by assuming the dimer unless otherwise stated.
Isothermal Titration Calorimetry
Thermodynamics 
Fluorescence spectroscopy
The PR concentration dependence of WT, Flap+ (I54A) , Flap+ (I54) and Flap+ (I54V) was examined by recording intrinsic tryptophan fluorescence emission on a FluoroMax-4 spectrofluoremeter (Horiba Scientific, Edison, NJ). Proteins, taken from a -80 °C frozen stock, were diluted, firstly to Structure was generated using PDB: 1T3R [65] . 
